For the quarter ending 2026-03-31, EMMA had -$1,055K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -3,335 | -1,951 | -2,076 | -3,465 |
| Tax benefit recognized on unrealized gain on debt securities | - | - | -578 | 591 |
| Depreciation and amortization | 15 | 15 | 15 | 9 |
| Inventory reserve | 4 | -111 | 4 | -4 |
| Amortization of discount of notes payable and convertible notes payable | 164 | 191 | 142 | 227 |
| (gain) loss on leased assets | - | 0 | 0 | 861 |
| Foreign exchange adjustments | 22 | 177 | 72 | -211 |
| Realized loss on investment in convertible bond | - | 0 | 0 | -531 |
| Loss on debt extinguishment | -76 | -691 | -296 | -376 |
| Share-based compensation | 1 | 7 | 9 | 9 |
| Change in fair value of warrant derivative liabilities | -2 | -2 | 2 | -5 |
| Change in fair value of conversion feature derivative, notes payable | -235 | 0 | 0 | 162 |
| Accounts receivable | -756 | 186 | 548 | -552 |
| Inventories | 351 | 449 | -109 | -319 |
| Prepaid expenses and other current assets | -294 | 600 | -84 | -376 |
| Other long-term liabilities | - | - | -401 | -419 |
| Other non-current assets | -30 | 10 | -31 | -302 |
| Accounts payable and accrued expenses | 1,873 | 1,578 | 2,414 | 2,464 |
| Other liabilities | -1 | 2,498 | -166 | -2,516 |
| Operating lease liabilities | -77 | -344 | - | - |
| Net cash flows used in operating activities | -344 | 2,209 | 409 | -2,629 |
| Proceeds from sale of convertible bond | - | 0 | 0 | 2,172 |
| Purchases of property and equipment | - | 0 | 0 | 1 |
| Net cash flows provided by investing activities | 0 | 0 | 0 | 2,171 |
| Proceeds from notes payable issued | 1,112 | 3,346 | 1,324 | 3,238 |
| Payments of notes payable | 1,796 | 3,708 | 2,326 | 2,849 |
| Payments of notes payable, related party | 9 | 0 | 0 | 240 |
| Payments of convertible notes | 9 | 0 | 0 | 210 |
| Net cash flows used in financing activities | -702 | -362 | -1,002 | -61 |
| Effect of exchange rate changes on cash | -9 | -13 | 1 | 15 |
| Net increase (decrease) in cash and cash equivalents | -1,055 | 1,834 | -592 | -504 |
| Cash and cash equivalents, beginning of year | 2,127 | 293 | 1,389 | - |
| Cash and cash equivalents, end of year | 1,072 | 2,127 | 293 | - |
Emmaus Life Sciences, Inc. (EMMA)
Emmaus Life Sciences, Inc. (EMMA)